|
Questions Raised About PPIs’ Link With Dementia Development
|
|
A new study has raised the possibility that long-term use of proton pump inhibitors (PPIs) could increase the risk of dementia. Past research on the issue has been mixed, and in this analysis no link to cognitive decline was found with short-term PPI use. Find out why researchers are urging more studies, especially since the use of PPIs is so widespread.
|
|
|
Tixagevimab/Cilgavimab Found Effective for Real-World COVID-19 Prophylaxis
|
|
|
At the end of 2021, the FDA approved tixagevimab/cilgavimab—marketed as Evusheld—to help prevent COVID-19 in moderately to severely immunocompromised patients and in patients for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reactions. A new veterans’ study demonstrated that the combination shows effectiveness in real-world use in a large cohort of immunocompromised patients. Read more.
|
|
FDA Approves First Oral Treatment for Postpartum Depression
|
|
|
The approval of a new treatment for postpartum depression provides another option for women suffering from the troubling condition. Previously, the only existing treatment was an IV injection available only in certain healthcare facilities. Find out what studies demonstrated concerning the effectiveness of zuranolone and when this agent is likely to be available for stocking by pharmacies.
|
|
|
Death Risk Post COVID-19 Hospitalization Higher Than That for Influenza
|
|
Older adults were much more likely to die after hospital discharge for COVID-19 than for influenza, according to a new study published in BMJ. Find out how much the risk of death declined as the pandemic continued and clinicians became better at treating the virus, vaccination became widespread, and SARS-Cov-2 itself changed.
|
|
.jpg)
